|
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Corxel Pharmaceuticals Ltd, RTW’s largest private investment, has completed Series D-1 financing worth $287 million. Says Corxel is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic conditions, and its lead candidate, CX11, is an oral GLP-1 receptor agonist for obese and overweight patients currently in a phase 2 US trial. Expects the financing proceeds to support the advancement of this trial, as well as a planned global phase 2 trial in type 2 diabetes mellitus and initial preparations for phase 3 studies and other cardiometabolic programmes. RTW says Corxel represents 6.2% of its net asset value as of December 31, and a quarter of its overall private investment exposure. Says it converted its convertible notes into Series D-1 shares as part of the financing. Its pro-forma holding in Corxel is valued at $53.9 million. Current stock price: $2.21 12-month change: up 67% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
